Logo image of APGE

APOGEE THERAPEUTICS INC (APGE) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:APGE - US03770N1019 - Common Stock

69.9 USD
-1.02 (-1.44%)
Last: 11/26/2025, 10:28:33 AM
Fundamental Rating

3

APGE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. APGE has a great financial health rating, but its profitability evaluates not so good. APGE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

APGE had negative earnings in the past year.
APGE had a negative operating cash flow in the past year.
APGE Yearly Net Income VS EBIT VS OCF VS FCFAPGE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -40.51%, APGE is in line with its industry, outperforming 59.47% of the companies in the same industry.
APGE has a Return On Equity of -43.26%. This is in the better half of the industry: APGE outperforms 69.61% of its industry peers.
Industry RankSector Rank
ROA -40.51%
ROE -43.26%
ROIC N/A
ROA(3y)-23.75%
ROA(5y)N/A
ROE(3y)-25.17%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
APGE Yearly ROA, ROE, ROICAPGE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -5 -10 -15 -20 -25

1.3 Margins

APGE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APGE Yearly Profit, Operating, Gross MarginsAPGE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

APGE has more shares outstanding than it did 1 year ago.
There is no outstanding debt for APGE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
APGE Yearly Shares OutstandingAPGE Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M 50M
APGE Yearly Total Debt VS Total AssetsAPGE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 200M 400M 600M

2.2 Solvency

APGE has an Altman-Z score of 69.48. This indicates that APGE is financially healthy and has little risk of bankruptcy at the moment.
APGE's Altman-Z score of 69.48 is amongst the best of the industry. APGE outperforms 97.94% of its industry peers.
There is no outstanding debt for APGE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 69.48
ROIC/WACCN/A
WACCN/A
APGE Yearly LT Debt VS Equity VS FCFAPGE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 15.86 indicates that APGE has no problem at all paying its short term obligations.
APGE's Current ratio of 15.86 is amongst the best of the industry. APGE outperforms 92.87% of its industry peers.
APGE has a Quick Ratio of 15.86. This indicates that APGE is financially healthy and has no problem in meeting its short term obligations.
APGE has a better Quick ratio (15.86) than 92.87% of its industry peers.
Industry RankSector Rank
Current Ratio 15.86
Quick Ratio 15.86
APGE Yearly Current Assets VS Current LiabilitesAPGE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for APGE have decreased strongly by -81.22% in the last year.
EPS 1Y (TTM)-81.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -14.72% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-39.23%
EPS Next 2Y-27.22%
EPS Next 3Y-24.05%
EPS Next 5Y-14.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
APGE Yearly Revenue VS EstimatesAPGE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
APGE Yearly EPS VS EstimatesAPGE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APGE. In the last year negative earnings were reported.
Also next year APGE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APGE Price Earnings VS Forward Price EarningsAPGE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APGE Per share dataAPGE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

APGE's earnings are expected to decrease with -24.05% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.22%
EPS Next 3Y-24.05%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for APGE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APOGEE THERAPEUTICS INC

NASDAQ:APGE (11/26/2025, 10:28:33 AM)

69.9

-1.02 (-1.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)03-02 2026-03-02/bmo
Inst Owners129.19%
Inst Owner Change2.28%
Ins Owners2.84%
Ins Owner Change-2.15%
Market Cap4.65B
Revenue(TTM)N/A
Net Income(TTM)-253.67M
Analysts89.41
Price Target97.21 (39.07%)
Short Float %16.45%
Short Ratio10.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.77%
Min EPS beat(2)-2.92%
Max EPS beat(2)8.47%
EPS beat(4)2
Avg EPS beat(4)5.62%
Min EPS beat(4)-8.41%
Max EPS beat(4)25.36%
EPS beat(8)4
Avg EPS beat(8)6.19%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.74%
PT rev (3m)-1.5%
EPS NQ rev (1m)17.41%
EPS NQ rev (3m)20.9%
EPS NY rev (1m)0%
EPS NY rev (3m)3.96%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.93
P/tB 7.93
EV/EBITDA N/A
EPS(TTM)-4.38
EYN/A
EPS(NY)-5.32
Fwd EYN/A
FCF(TTM)-3.57
FCFYN/A
OCF(TTM)-3.49
OCFYN/A
SpS0
BVpS8.81
TBVpS8.81
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -40.51%
ROE -43.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-23.75%
ROA(5y)N/A
ROE(3y)-25.17%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 467.28%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.86
Quick Ratio 15.86
Altman-Z 69.48
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-81.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.07%
EPS Next Y-39.23%
EPS Next 2Y-27.22%
EPS Next 3Y-24.05%
EPS Next 5Y-14.72%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-59.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-37.16%
EBIT Next 3Y-17.83%
EBIT Next 5YN/A
FCF growth 1Y-129.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-128.96%
OCF growth 3YN/A
OCF growth 5YN/A

APOGEE THERAPEUTICS INC / APGE FAQ

What is the ChartMill fundamental rating of APOGEE THERAPEUTICS INC (APGE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to APGE.


What is the valuation status for APGE stock?

ChartMill assigns a valuation rating of 0 / 10 to APOGEE THERAPEUTICS INC (APGE). This can be considered as Overvalued.


Can you provide the profitability details for APOGEE THERAPEUTICS INC?

APOGEE THERAPEUTICS INC (APGE) has a profitability rating of 1 / 10.


Can you provide the financial health for APGE stock?

The financial health rating of APOGEE THERAPEUTICS INC (APGE) is 8 / 10.


Can you provide the expected EPS growth for APGE stock?

The Earnings per Share (EPS) of APOGEE THERAPEUTICS INC (APGE) is expected to decline by -39.23% in the next year.